Abstract
Mucosal healing has emerged as an important outcome measure of treatment in inflammatory bowel disease (IBD). It is increasingly incorporated in the outcome measures of clinical trials along with patient reported outcomes and used in clinical practice as a therapeutic target or goal. The exact definition of mucosal healing continues to evolve and several scoring systems have been developed, some of which require further validation. Considerable inter-observer variation may also exist in interpretation of mucosal appearance in IBD. Novel endoscopic techniques demonstrate that even in patients who have achieved mucosal healing by conventional criteria, subtle inflammation may continue to persist. Whether mucosal healing needs to incorporate or reflect histological healing is a topic of intense debate and further studies. In addition, surrogate markers of mucosal healing, such as fecal calprotectin, may serve as a therapeutic target, but there is debate about whether normalization of fecal calprotectin always reflects mucosal healing. Patients with mucosal healing may also continue to have clinical symptoms reflecting visceral hypersensitivity.
References
1.
Iacucci M, Panaccione R, Ghosh S: Advances in novel diagnostic endoscopic imaging techniques in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:873-880.
2.
Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group: Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-422.
3.
Odenwald MA, Turner JR: Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol 2013;11:1075-1083.
4.
Jostins L, Ripke S, Weersma RK, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
5.
Shen L, Su L, Turner JR: Mechanisms and functional implications of intestinal barrier defects. Dig Dis 2009;27:443-449.
6.
Butler M, Ng CY, van Heel DA, Lombardi G, Lechler R, Playford RJ, Ghosh S: Modulation of dendritic cell phenotype and function in an in vitro model of the intestinal epithelium. Eur J Immunol 2006;36:864-874.
7.
Shale M, Ghosh S: How intestinal epithelial cells tolerise dendritic cells and its relevance to inflammatory bowel disease. Gut 2009;58:1291-1299.
8.
Peyrin-Biroulet L, Sandborn W, Sands BE, et al: Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-1338.
9.
Arnott ID, Watts D, Ghosh S: Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002;16:857-867.
10.
Jones J, Loftus EV Jr, Panaccione R, et al: Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-1224.
11.
Sturm A, Dignass AU: Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol 2008;14:348-353.
12.
Dulai PS, Levesque BG, Feagan BG, et al: Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015;82:246-255.
13.
Rutgeerts P, Van Assche G, Sandborn WJ, et al: Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-1111.
14.
Colombel JF, Rutgeerts PJ, Sandborn WJ, et al: Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:414-422.
15.
Feagan BG, Sandborn WJ, D'Haens G, et al: The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149-157.
16.
Takenaka K, Ohtsuka K, Kitazume Y, et al: Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease. Gastroenterology 2014;147:334-342.
17.
Sipponen T: Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013;31:336-344.
18.
Theede K, Holck S, Ibsen P, et al: Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:1929-1936.
19.
Falvey JD, Hoskin T, Meijer B, et al: Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis 2015;21:824-831.
20.
Dai C, Liu WX, Jiang M, Sun MJ: Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One 2014;9:e110797.
21.
Iacucci M, Fort Gasia M, Hassan C, et al: Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. Endoscopy 2015;47:726-734.
22.
Osterman MT, Aberra FN, Cross R, et al: Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2014;12:1887-1893.
23.
Ordás I, Rimola J, Rodríguez S, et al: Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014;146:374-382.
24.
Mojtahed A, Khanna R, Sandborn WJ, et al: Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis 2014;20:2092-2103.
25.
Vuitton L, Marteau P, Sandborn WJ, et al: IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 2015;pii:gutjnl-2015-309903.
26.
Bryant RV, Burger DC, Delo J, et al: Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2015;pii:gutjnl-2015-309598.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
